Featuring: Molly Shoichet, PhD, O.C., O. Ont., FRS, University Professor and Pamela & Paul Austin Chair in Precision & Regenerative Medicine, University of Toronto Audrey Greenberg, MBA, CEO & Founder, AG Capital Advisors *** In this engaging episode of “Commercializing Living Therapies with CCRM,” we sit down with two leaders in the life sciences field: Molly Shoichet, a biomedical engineer and University Professor at the University of Toronto, and Audrey Greenberg, Founder and M...

Reni Benjamin, Managing Director, Healthcare Equity Research at Citizens Brock Reeve, CEO and Co-founder, Eos BioInnovation *** In this episode of Commercializing Living Therapies with CCRM, host Krista Lamb speaks with Reni Benjamin and Brock Reeve about the current financial landscape for cell and gene therapies (CGTs). They explore the unique dynamics companies face, from securing funding to navigating regulatory hurdles, and discuss how investors assess risks and opportunities in the fiel...

Featuring: Silvio Tiziani, CEO, CCRM Australia Sarah Callens, CTO, CCRM Nordic *** In this episode of Commercializing Living Therapies with CCRM, Silvio Tiziani, CEO, CCRM Australia, and Sarah Callens, CTO, CCRM Nordic, explore the opportunities and challenges of commercializing regenerative medicines, including cell and gene therapies, in their respective regions. While scientific discoveries abound, barriers such as regulatory hurdles, funding gaps and infrastructure limitations can slow th...

Featuring: Durhane Wong-Rieger, PhD, President and CEO, Canadian Organization for Rare Disorders Jacqueline Barry, PhD, Chief Clinical Officer, Cell and Gene Therapy Catapult *** In this episode, we dive into the critical topic of enabling patient access to cell and gene therapies with two leaders in the field. Jacqueline Barry, an expert in the development and adoption of advanced therapies, shares her insights on the challenges involved with bringing innovative treatments to patients, from ...

Featuring:Paul Knoepfler, PhD, Professor of Cell Biology and Human Anatomy, UC Davis School of MedicineAmy Zarzeczny, PhD LLM, Associate Professor, Johnson Shoyama Graduate School of Public Policy, University of Regina***Unapproved stem cell therapies continue to be a significant concern in the regenerative medicine field. In this episode, Drs. Paul Knoepfler and Amy Zarzeczny discuss the issue. Listeners will hear the risks and implications of these treatments, and why they are not just...

Featuring:Christopher P. Boone, PhD, Group Vice President, Research Services, Health & Life Sciences, OracleKenneth L. Harris, Chief Strategy Officer and Head of AI, OmniaBio Inc. ***We are excited to share the first episode in the fourth season (!) of Commercializing Living Therapies with CCRM. A big thanks to all our listeners.In this episode, we explore how artificial intelligence (AI) and robotics are shaping the biomanufacturing facility of the future. Our guests discuss the tec...

Featuring:Jacki Jenuth, PhD, Partner and COO, Lumira VenturesRobin Quirk, PhD MBA, Vice President, Technology Sourcing and Venture Development, CCRM***In this episode, we explore the dynamics of venture capital (VC) and company creation with Jacki Jenuth, Partner and COO, Lumira Ventures, and Robin Quirk, Vice President, Technology Sourcing and Venture Development, CCRM. The conversation covers the essence of venture capital funding, from how VCs evaluate investment potential to crucial consi...

Featuring:Michael Rosu-Myles, PhD, Executive Director, Health CanadaJosephine Lembong, PhD, Senior Manager, Science and Industry Affairs, Alliance for Regenerative Medicine***Currently, there are more than 2,000 cell and gene therapies in clinical trials worldwide. With a goal of ensuring that safe and quality products are approved for use by patients, regulators determine whether these innovative therapies move from the lab to market.In this interview, Michael Rosu-Myles, PhD, Executive Dire...

Featuring:Sonia Sennik, Executive Director, Creative Destruction LabGlenn MacLean, Director, Technology Sourcing and Venture Development, CCRM***In many science-oriented fields, including regenerative medicine and advanced therapies, researchers and company founders often require additional support and expertise to successfully commercialize their discoveries. With a mission of enhancing the commercialization of science for the betterment of humankind, Creative Destruction Lab is a valua...

Featuring:Matthew Durdy, Chief Executive Officer, Cell and Gene Therapy CatapultMichael May, PhD, President and Chief Executive Officer, CCRM***Public-private partnerships are collaborations between government agencies and private-sector companies. In this interview, Matthew Durdy, CEO, Cell and Gene Therapy Catapult, and Michael May, President and CEO, CCRM, explain how these collaborations have had an impact in the regenerative medicine sector by advancing cell and gene therapies along the ...

Featuring:Matthew Miller, B.M.Sc., PhD, Director, Michael G. DeGroote Institute for Infectious Disease Research; Co-Director, Canadian Pandemic Preparedness Hub (CP2H), McMaster University Patrycja Thompson, PhD, Director, Strategy & Operations, the Canadian Hub for Health Intelligence & Innovation in Infectious Diseases (HI3), University of Toronto***The COVID-19 pandemic illuminated a need to scale up Canada’s biomanufacturing capacity. As a response, the Government of Canada e...

Featuring:Mamatha Bhat MD, MSc, PhD, FRCPCHepatologist & Co-Lead of Transplant AI initiative (TAI), Ajmera Transplant Program Scientist, Toronto General Hospital Research Institute, University Health NetworkAssociate Professor, Division of Gastroenterology & HepatologyDirector, Clinician-Scientist Training Program (CSTP), Department of Medicine, University of TorontoPartnerships & Engagement Lead, Temerty Centre for AI in Research & Education in Medicine (T-CAIREM); Faculty Af...

Featuring:Tom Whitehead, Co-Founder, Emily Whitehead Foundation. Courtney Horvath, PhD, Global Head of Strategy, Planning & Operations, Translational Medicine, Novartis. In this episode, we hear from two parents who supported their children through cancer treatments. Listeners will hear their unflinching accounts of what the children went through, underlining the urgent need for access to innovative and less toxic treatments.Tom is the co-founder of the Emily Whitehead Foundatio...

Featuring:Dr. Joerg Krueger, Medical Director, CAR T-Cell Program, The Hospital for Sick Children. Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine.Our guests discuss the future of CAR T-cell therapies, in a conversation covering autologous and allogeneic CAR T therapies. Drs. Krueger and Levine share their thoughts on which of these two approaches is likely to pull ahead in the years to come, while ackno...

Featuring:Mark Taylor, Director of Commercialization, University Health Network Dr. Irja Elliott Donaghue Technical & IP Specialist and Patent Agent, Notch TherapeuticsIn the past, there was little evidence to challenge the idea that if a therapeutics developer did not hold a patent, it did not have anything to commercialize. In this episode, guests outline how the regenerative medicine industry changed that, proving the belief to be outdated, with some innovation being better protec...

Featuring:Dr. Dolores Baksh, CEO of TAAV Biomanufacturing SolutionsSusan Nichols, Chief Business Officer at ViroCell BiologicsAs the cell and gene therapy industry continues to grow rapidly, Dolores Baksh and Susan Nichols emphasize the importance of nurturing a new workforce equipped with the skills to pivot and persevere—crucial qualities for the industry to grow. Join our guests as they discuss the significance of mentorship in the cell and gene therapy space, which mentorship programs the...

Featuring: Dr. Lise Munsie, Vice President, iPSC Technology Platform, CCRM Dr. Stephen Sullivan, Programme Manager, Global Alliance for iPSC Therapies (GAiT) Drs. Lise Munsie and Stephen Sullivan explore some of the biggest challenges that will need to be addressed to unlock the potential of induced pluripotent stem cells (iPSCs), from regulatory issues to quality assurance and safety. Listen to hear about the proactive approach CCRM takes with its iPSC Excellence Team. You’ll also...

Featuring: Dr. Qasim Rafiq, Associate Professor in Cell and Gene Therapy Bioprocess Engineering, University College London (UCL)Dr. Christine Allen, Vice-President, Ecosystem Development, adMare BioInnovationsDrs. Christine Allen and Qasim Rafiq offer insight on how to train and retain tomorrow’s cell and gene therapy (CGT) workforce in a very competitive space. We’ve witnessed an “explosion” of activity and they believe it’s up to industry to address the skills gap and to focus on train...

How will Canada’s health care system pay for cell and gene therapy cures? Featuring: Dr. Chris McCabe, CEO and Executive Director, Institute of Health Economics Robert Woolstencroft, Senior Director and Head, Market Access and Reimbursement, Gilead Sciences Canada Our guests tackle the complex question of how therapy developers working at the cutting edge of regenerative medicine can get reimbursed when they deliver on the promise of cures. How can patients on Prince Edwa...

Examining the role ethical considerations and regulatory frameworks will play in regenerative medicine’s future.Featuring: Prof. Bartha Maria Knoppers, Canada Research Chair in Law and Medicine, and Director of the Centre of Genomics and Policy, Faculty of Medicine, McGill University Siofradh McMahon, Director, Clinical Translation and Regulatory Affairs, CCRM Join guests for a discussion about the responsibilities of the regenerative medicine industry, exploring how ethics ca...